Biocept

The firm is offering  24.6 million shares of its common stock and warrants to purchase 24.6 million shares of stocks to financially  support and expand its business.

The San Diego-based company said that the number of commercial samples received during the quarter grew 66 percent year over year.

The tubes and collection kits meet the requirements of the European In-Vitro Diagnostic Devices Directive, and the company can now commercialize the devices throughout Europe.

The company said it will use the net proceeds for general corporate purposes and to fund ongoing operations and expansion of its business.

The firm has a 180-day grace period in which to regain compliance, by maintaining a $1.00 minimum closing bid price for at least 10 consecutive business days.

Buoyed by a 26 percent increase in test volume, the firm's revenues were $1.2 million for the quarter, compared to $822,000 last year.

Shares jumped nearly 90 percent today after the firm said this morning that it has commercially launched its Target Selector NGS Lung Panel assay.